My Kesimpta

In mid-2021, Novartis Neuro launched a new product for relapsing Multiple Sclerosis. KESIMPTA (Ofatumumab) is an auto-injection treatment.

The challenge was to reassure prescribers as per the ease of administration and ensure good patient compliance.

A gated patient application available on public App stores for Kesimpta patients to provide auto-injection training, product information and assistance. Integrated features to enhance the user experience:

• An interactive 3D model of the pen.
• Augmented reality experience.
• A 3D MOA video (supplied by the customer).
• A simulator to practice handling.
• Voice assistant to guide patients through injections.